Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for shares of ADC Therapeutics in a note ...

ADC Therapeutics (NYSE:ADCT – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Guggenheim lowered the firm’s price target on ADC Therapeutics (ADCT) to $7 from $10 and keeps a Buy rating on the shares. Q4 results were ...

Despite flat revenue growth, ADC Therapeutics SA (ADCT) strengthens its financial position with reduced losses and promising trial data.

Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...